EGFR and non-small cell lung carcinoma: Since in NSCLC, in addition to EGFR, a number of additional gene alterations, such as mutations in ALK, BRAF, KRAS (G12C), and MET; gene fusions involving ALK, ROS1, NTRK1, NTRK2, NTRK3, and RET; and exon 14 skipping in MET, can be targeted by drugs available for clinical use, next-generation sequencing (NGS) was the main methodological approach employed in this study.